Skip to main content
. 2017 Mar 31;7:45768. doi: 10.1038/srep45768

Table 2. Expression rates of mesothelioma markers in non-MPM tumors.

  SKM9-2 antigen Calretinin CK5/6 Podoplanin WT-1 Mesothelin
Lung carcinoma 0/98 23/98 41/98 13/98 0/98 44/98
Renal cell carcinoma 0/10 0/10 1/10 0/10 0/10 0/10
Gastric adenocarcinoma 0/10 2/10 7/10 6/10 0/10 1/10
Colon adenocarcinoma 0/10 0/10 0/10 0/10 0/10 0/10
Breast cancer 0/10 1/10 2/10 0/10 1/10 0/10
Ovary adenocarcinoma 0/10 0/10 7/10 1/10 3/10 6/10
Urothelial carcinoma 1/10 2/10 7/10 0/10 0/10 0/10
Carcinosarcoma 0/10 3/10 6/10 2/10 2/10 3/10
Liposarcoma 0/10 6/10 1/10 1/10 1/10 0/10
Rhabdomyosarcoma 0/10 1/10 0/10 2/10 1/10 0/10
Leiomyosarcoma 1/10 1/10 0/10 2/10 0/10 0/10
Fibrosarcoma 0/10 2/10 0/10 0/10 1/10 0/10
Synovial sarcoma 0/10 2/10 2/10 5/10 1/10 2/10
Gastrointestinal stromal tumor (GIST) 0/9 0/9 0/9 1/9 1/9 0/9
Ewing’s sarcoma 0/10 1/10 0/10 2/10 0/10 0/10
Alveolar soft part sarcoma (ASPS) 0/10 0/10 0/10 0/10 0/10 0/10
Solitary fibrous tumor 0/10 0/10 0/10 3/10 0/10 0/10
Malignant peripheral nerve sheath tumor (MPNST) 0/10 2/10 2/10 4/10 0/10 0/10
Angiosarcoma 0/10 3/10 2/10 7/10 0/10 0/10
Chondrosarcoma 0/10 0/10 0/9 8/10 0/7 0/10
Osteosarcoma (OS) 0/10 0/10 0/10 4/10 0/10 0/10
Epithelioid hemangioendothelioma 1/6 0/6 3/6 2/6 0/6 0/6
Epithelioid angiosarcoma 0/2 2/2 2/2 1/2 0/2 0/2
Biphasic synovial sarcoma 0/5 4/5 4/5 2/5 0/5 4/5
Total 3/310 55/310 87/309 66/310 11/307 60/310
Specificity 99% 82% 72% 79% 96% 81%

Intensity and proportion of staining in tumor cells were evaluated in the entire microscopic field of each specimen. Cases were defined as positive if the proportion score was more than 0. In the immunostaining of calretinin or WT-1, staining in the nucleus, but not the cytoplasm, was considered a positive sample.